Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Operating Leases (2019 - 2025)

Historic Operating Leases for Sanofi (SNY) over the last 7 years, with Q4 2025 value amounting to $1.7 billion.

  • Sanofi's Operating Leases fell 284.62% to $1.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year decrease of 284.62%. This contributed to the annual value of $1.7 billion for FY2025, which is 688.52% down from last year.
  • As of Q4 2025, Sanofi's Operating Leases stood at $1.7 billion, which was down 284.62% from $1.7 billion recorded in Q2 2025.
  • In the past 5 years, Sanofi's Operating Leases ranged from a high of $2.4 billion in Q4 2021 and a low of $1.5 billion during Q2 2021
  • For the 5-year period, Sanofi's Operating Leases averaged around $1.9 billion, with its median value being $1.9 billion (2023).
  • Its Operating Leases has fluctuated over the past 5 years, first soared by 4339.28% in 2021, then crashed by 1513.98% in 2023.
  • Over the past 5 years, Sanofi's Operating Leases (Quarter) stood at $2.4 billion in 2021, then decreased by 7.73% to $2.2 billion in 2022, then decreased by 15.14% to $1.9 billion in 2023, then fell by 6.91% to $1.8 billion in 2024, then dropped by 2.85% to $1.7 billion in 2025.
  • Its Operating Leases stands at $1.7 billion for Q4 2025, versus $1.7 billion for Q2 2025 and $1.8 billion for Q4 2024.